← FDA DRUG APPROVALS

FDA ANDA · ANDA204549

GEMCITABINE HYDROCHLORIDE

Sponsor: ACTAVIS INC

APPLICATION
ANDA204549
TYPE
ANDA
ORIGINAL APPROVAL
2016-04-11
LATEST ACTION
2026-07-17
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE 2GM/52.6ML (38MG/ML) · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE 200MG/5.26ML (38MG/ML) · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE 1GM/26.3ML (38MG/ML) · INJECTABLE · INJECTION

Approval history

2026-07-17Labeling · Supplement 5 · standardAP
2020-06-23Labeling · Supplement 3 · standardAP
2019-05-03Labeling · Supplement 2 · standardAP
2016-04-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →